| EX1165 IMMUNOHISTOCHEMISTRY: DIGITAL BREAST CANCER PANEL 4 |
| Specimen: |
Submit Tissue in 10% formal-saline OR formalin-fixed paraffin-embedded Tissue Block. Ship at room temperature. |
| Stability: |
| Room |
Refrigerated |
Frozen |
| NA |
NA |
NA |
|
| Method: |
Light Microscopy, IHC, Digital Photography |
| Comment: |
Photographs with AI read-out will be provided. Samples received on holidays will be reported in the next schedule / next working day. |
| Report: |
Contact us to know the TAT. |
| Usage: |
ER & PR receptor assays are routinely performed on Breast carcinoma to assess responsiveness to endocrine therapy and prognosis. Her-2 expression predicts responsiveness to Herceptin therapy. Ki-67 in addition is a useful prognostic marker. Together ER, PR, Her-2, and Ki 67 help to predict prognosis and serve as surrogate IHC markers for molecular subtypes of Breast Cancer. Reporting through digital images using Visiopharm AI algorithms enhances the sensitivity of the assay. |
| Doctor Specialty: |
Oncologist |
| Disease: |
Cancer |
| Components: |
*ER *PR *HER-2 *Ki67 *Photomicrograph *Includes Pathologist review for presence of malignant cells |
| Courier Charges: |
|
| Home Collection: |
Available (*T&C Apply) |
| Department: |
Histopathology |
| Pre Test Information: |
Provide a copy of the Histopathology report, Site of biopsy, and Clinical history. |
Reviews
There are no reviews yet.